Regulatory timeline
Federal safety actions on COVID-19 vaccines, in order: signals, pauses, recommendations, warnings, label changes, restrictions and withdrawals — with whether each is still current, was superseded, or was a signal later evaluation did not confirm. A preliminary signal is never shown as an established finding.
Topic: All · Myocarditis and pericarditis · Blood clots and thrombosis with thrombocytopenia (TTS) · Stroke · Guillain-Barré syndrome
Agency: FDA · CDC
Threads: janssen tts · myocarditis · janssen gbs · stroke signal
-
CDC and FDA recommend pausing the Janssen (J&J) vaccine after rare clots with low platelets
Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: All recipients
What changed: Use paused while six reported cases of cerebral venous sinus thrombosis with low platelets were reviewed.
CDC and FDA recommended pausing the vaccine “out of an abundance of caution” while reviewing six U.S. reports of cerebral venous sinus thrombosis with thrombocytopenia among more than 6.8 million doses.
A pause to investigate is not a finding that the vaccine caused the events.
-
FDA and CDC lift the Janssen pause and add a clotting warning
Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: All recipients
What changed: Use resumed; fact sheets updated with information on the risk of thrombosis with thrombocytopenia.
After two ACIP meetings and a safety review, the agencies lifted the pause and added information about the rare clotting risk to the vaccine's fact sheets.
Superseded by the May 2022 restriction.
Later: FDA restricted the vaccine's use on May 5, 2022.
-
FDA adds a myocarditis and pericarditis warning to Pfizer and Moderna fact sheets
Product: Pfizer-BioNTech and Moderna COVID-19 vaccines · Population: Recipients, particularly after dose 2 and in young males
What changed: Provider fact sheets gained a myocarditis/pericarditis warning; recipient fact sheets gained information on symptoms.
FDA revised both mRNA vaccines' fact sheets after ACIP reviewed reports suggesting increased risks of myocarditis and pericarditis, particularly after the second dose and with onset within a few days.
Later labeling (2025) added incidence estimates.
Later: Labeling updated with incidence estimates on June 25, 2025.
-
Guillain-Barré syndrome warning added for the Janssen vaccine; ACIP reaffirms its use
Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: Adult recipients
What changed: Fact sheets revised to describe an observed increased risk of Guillain-Barré syndrome in the 42 days after vaccination.
FDA revised the Janssen fact sheets to note an observed increased risk of Guillain-Barré syndrome in the 42 days after vaccination; ACIP reviewed the data and concluded benefits outweighed risks.
Superseded by the 2022 restriction and the 2023 revocation of the Janssen authorization.
Later: The Janssen authorization was restricted in 2022 and revoked in 2023.
-
FDA limits use of the Janssen (J&J) COVID-19 vaccine because of thrombosis with thrombocytopenia syndrome
Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: Adults 18 and older
What changed: Authorized use narrowed to adults without access to, or clinically unable to receive, other COVID-19 vaccines, or who would otherwise not be vaccinated.
FDA limited authorized use of the Janssen vaccine to adults for whom other COVID-19 vaccines were not accessible or clinically appropriate, or who would otherwise not be vaccinated, after determining that the risk of thrombosis with thrombocytopenia syndrome (rare, potentially life-threatening clots with low platelets, with onset about one to two weeks after vaccination) warranted the restriction.
The Janssen vaccine is no longer authorized for use in the United States; this record documents the 2022 regulatory finding.
Later: FDA revoked the Janssen EUA at the company's request on June 1, 2023.
-
Novavax vaccine authorized with a myocarditis and pericarditis warning
Product: Novavax COVID-19 Vaccine, Adjuvanted · Population: Recipients
What changed: Authorized with a warning that clinical-trial data provide evidence for increased risks of myocarditis and pericarditis.
The Novavax fact sheet warns that clinical-trial data provide evidence for increased risks of myocarditis and pericarditis; six cases were detected among 41,546 trial recipients aged 16 and older.
Trial case counts are small; the wording is the regulator's.
-
CDC and FDA report a preliminary ischemic-stroke signal for Pfizer's bivalent booster in people 65+
Product: Pfizer-BioNTech COVID-19 Vaccine, Bivalent · Population: People 65 and older
What changed: No change to recommendations; the signal was investigated in other databases.
CDC's Vaccine Safety Datalink flagged a possible increase in ischemic stroke 1–21 days after Pfizer's bivalent booster in people 65 and older. Medicare and VA analyses did not find an increased risk, and as data accumulated the agencies said the evidence did not support a safety issue.
A preliminary signal from near-real-time surveillance is not a finding; this one was not confirmed by other systems.
-
FDA revokes the Janssen vaccine's emergency authorization at the company's request
Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: All
What changed: Emergency use authorization revoked; the vaccine is no longer available in the United States.
Janssen asked FDA to withdraw the authorization because the last U.S. government lots had expired, there was no demand, and it did not intend to update the vaccine; FDA revoked it.
The stated reasons were commercial and supply-related, not a new safety finding.
-
FDA requires updated myocarditis and pericarditis warning for mRNA COVID-19 vaccines
Product: Comirnaty (Pfizer-BioNTech); Spikevax (Moderna) · Population: Recipients of mRNA COVID-19 vaccines; highest estimated incidence in males 12–24
What changed: Warnings in Comirnaty and Spikevax labeling updated with incidence estimates and cardiac MRI follow-up results; EUA fact sheets for children 6 months–11 years updated.
FDA approved required labeling changes adding an estimated unadjusted incidence of myocarditis and/or pericarditis after the 2023–2024 formula of mRNA COVID-19 vaccines — about 8 cases per million doses in people 6 months through 64 years old, and about 27 cases per million doses in males 12 through 24 — and results of a cardiac MRI study in which abnormal findings often persisted at about five months.
FDA states that the clinical and prognostic significance of the persistent MRI findings is not known and that longer-term studies are under way.
Thread: janssen tts
- Pause — CDC and FDA recommend pausing the Janssen (J&J) vaccine after rare clots with low platelets Lifted
- Warning — FDA and CDC lift the Janssen pause and add a clotting warning Superseded
- Restriction — FDA limits use of the Janssen (J&J) COVID-19 vaccine because of thrombosis with thrombocytopenia syndrome Superseded
- Withdrawal — FDA revokes the Janssen vaccine's emergency authorization at the company's request Withdrawn
Thread: myocarditis
- Warning — FDA adds a myocarditis and pericarditis warning to Pfizer and Moderna fact sheets Superseded
- Authorization — Novavax vaccine authorized with a myocarditis and pericarditis warning Current
- Label change — FDA requires updated myocarditis and pericarditis warning for mRNA COVID-19 vaccines Current
Thread: janssen gbs
- Warning — Guillain-Barré syndrome warning added for the Janssen vaccine; ACIP reaffirms its use Superseded
Thread: stroke signal
- Signal — CDC and FDA report a preliminary ischemic-stroke signal for Pfizer's bivalent booster in people 65+ Signal not confirmed